Takeaway
Leukocyte telomere length (LTL) in Huntington’s disease (HD) is correlated with disease state, with a shorter LTL in symptomatic HD (manifest HD) than in mutation carriers (pre-manifest HD) or healthy individuals.
Why this matters
Monitoring of LTL in pre-manifest HD patients may provide a biomarker for: monitoring disease progression, predicting the onset of symptoms, and evaluating disease-modifying therapeutics.